Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation

Health Technology Assessment

Volumn 12, Issue 16, 2008, Pages

  Colquitt, J L ^a   Jones, J ^a   Tan, S C ^a   Takeda, A ^a   Clegg, A J ^a   Price, A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PEGAPTANIB; RANIBIZUMAB; STEROID; VERTEPORFIN; APTAMER; MONOCLONAL ANTIBODY;

BLEEDING; BLEPHARITIS; BLINDNESS; BLURRED VISION; BRAIN INFARCTION; CATARACT; CHOROID HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CORNEA EDEMA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DETERIORATION; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; ENDOPHTHALMITIS; EYE DISCHARGE; EYE DISEASE; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE SURGERY; FOLLOW UP; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; INJECTION SITE REACTION; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; IRITIS; LACRIMATION; LASER COAGULATION; LENS DISEASE; LOW LEVEL LASER THERAPY; MONOTHERAPY; NATIONAL HEALTH SERVICE; OCULAR FIBROSIS; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PUNCTATE KERATITIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA TEAR; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY; VISUAL DISORDER; VITRECTOMY; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; VITREOUS OPACITY; AGE; CONTRAST SENSITIVITY; DRUG EFFECT; ECONOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL ACUITY;

EID: 46949111802     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta12160     Document Type: Review

References (153)

1. Evans J, Wormald R. Is the incidence of registrable age related macular degeneration increasing? Br J Ophthalmol 1996;80:9-14.
2. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system of age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-74.
3. Fine SL, Berger KW, Maguire MG, Ho AC. Age related macular degeneration. New Engl J Med 2000;342(7):483-92.
4. Evans J. Age-related macular degeneration. In Johnson GJ, Minassian DC, Weale R, editors. The epidemiology of eye disease. London: Chapman and Hall; 1998. pp. 356-72.
5. Klaver CCW, Assink JJM, van Leeuwen R, Wolfs RCW, Vingerling JR, Stijnen T, et al. Incidence and progression rates of age-related maculopathy: The Rotterdam Study. Invest Ophthalmol Vis Sci 2001;42:2237-41.
6. van Leeuwen R, Klaver CCW, Vingerling JR, Hofman A, de Jong PTVM. The risk and natural course of age-related maculopathy: follow-up at 61/2 years in the Rotterdam study. Arch Ophthalmol 2003; 121:519-26.
7. Augood CA, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006;124:529-35.
8. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-2.
9. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-93.
10. Arnold J, Blemenkranz M, Bressler NM, Bressler SB, Deslandes J, Donati G, et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol 1999;117:1329-45.
11. Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004;111:250-5.
12. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eve Disease Study (AREDS). AREDS Report No. 19. Ophthalmology. 2005;112:533-9.
13. Brown MD, Bowling EL. Age-related macular degeneration - a therapeutic update. Clin Refract Optom 2005;16:240-8.
14. Delcourt C, Diaz J, Ponten-Sanchez A, Papoz L. Smoking and age-related macular degeneration: the POLA study. Arch Ophthalmol 1998; 116:1031-5.
15. Schmidt S, Hauser MA, Scott WK, Postel EA, Agarwal A, Gallins P, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet 2006; 78:852-64.
16. Evans JR, Henshaw K. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev 1999;(4):CD000253.
17. Age-Related Eye Disease Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS Report No. 8. Arch Ophthalmol 2001;119:1417-36.
18. Evans J. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2000;(2):CD000254.
19. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 203;121:785-92.
20. Seddon JM, George S, Rosner B, Klein ML. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered 2006;61:157-65.
21. Hyman L, Schachat AP, He Q, Leske MC, for the Age-Related Macular Degeneration Risk Factors Study Group. Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol 2000;118:351-8.
22. Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina 2005;25:1065-84.
23. Royal College of Ophthalmologists. Age related macular degeneration. Guidelines. London: Royal College of Ophthalmologists; 2000.
24. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2002;109:1767-79.
25. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 2002; 109:1092-7.
26. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England and Wales. BMC Public Health 2006; 6:58.
27. Owen CG, Fletcher AE, Donoghue M, Rudnika AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87:312-17.
28. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43.
29. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102:1450-60.
30. Vinding T. Visual impairment of age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol 1990; 68:162-7.
31. Vinding T. Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors. Acta Ophthalmol Scand Suppl 1995;(217):1-32.
32. Reidy A, Minassian DC, Vafidis G, Joseph J, Farrow S, Wu J, et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ 1998;316:1643-6.
33. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205-10.
34. Vannewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000;107:1593-600.
35. Vannewkirk MR, Weih L, McCarty CA, Taylor HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project. Ophthalmology 2001; 108:960-7.
36. Weih LM, Vannewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000; 118:264-9.
37. Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 2001; 108:2347-57.
38. Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 1989;107:847-52.
39. Office for National Statistics. Mid-2005 population estimates: England and Wales; estimated resident population by single year of age and sex. URL: http://www.statistics.gov.uk/statbase/Expodata/ Spreadsheets/D9389.xls. Accessed 16 October 2006.
40. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2001;7(9).
41. Morse AR, Yatzkan E, Berberich B, Arons RR. Acute care hospital utilization by patients with visual impairment. Arch Ophthalmol 1999; 117:943-9.
42. Wang JJ, Mitchell P, Cumming RG, Attebo K. Impact of visual impairment on use of community support services by elderly persons: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 1999; 40:12-19.
43. Wang JJ, Mitchell P, Cumming RG, Smith W. Visual impairment and nursing home placement in older Australians: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003;10:3-13.
44. Wang JJ, Mitchell P, Simpson JM, Cumming RG, Smith W. Visual impairment, age-related cataract, and mortality. Arch Ophthalmol 2001; 119:1186-90.
45. Zhou S, Javitt JC, Zlateva G, Shah SN. Evaluating the risk of mortality for exudative (wet) AMD patients compared to a control group, Invest Ophthalmol Vis Sci 2006;47:2213.
46. Thiagarajan M, Evans JR, Smeeth L, Wormald RPL, Fletcher AE. Cause-specific visual impairment and mortality: results from a population-based study of older people in the United Kingdom. Arch Ophthalmol 2005; 123:1397-403.
47. Centers for Medicare and Medicaid Services. Standard analytical files - limited data set. URL: http://www.cms.hhs.gov/LimitedDataSets/ 10_StandardAnalyticalFiles.asp. Accessed 10 October 2006.
48. Jack CI, Smith T, Neoh C, Lye M, McGalliard JN. Prevalence of low vision in elderly patients admitted to an acute geriatric unit in Liverpool: elderly people who tall are more likely to have low vision. Gerontology 1995;41:280-5.
49. Tromp AM, Pluijm SM, Smit JH, Deeg DJ, Bouter LM, Lips P. Fall-risk screening test: a prospective study on predictors for falls in community-dwelling elderly. J Clin Epidemiol 1995; 54:837-44.
50. Legood R, Scuffham P, Cryer C. Are we blind to injuries in the visually impaired? A review of the literature. Inj Prev 2002; 8:155-60.
51. Ivers RQ, Optom B, Cumming RG, Mitchell P, Simpson JM, Peduto AJ. Visual risk factors for hip fracture in older people. J Am Geriatr Soc 2003; 51:356-63.
52. Felson DT, Anderson JJ, Hannan MT, Milton RC, Wilson PW, Kiel DP. Impaired vision and hip fracture. The Framingham Study. J Am Geriatr Soc 1989;37:495-500.
53. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:707-73.
54. Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996;348:145-9.
55. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; 108:1893-900.
56. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998; 116:514-20.
57. Rovner BW, Ganguli M. Depression and disability associated with impaired vision: the moVIES project. J Am Geriatr Soc 1998; 46:617-19.
58. Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol 2004; 15:181-3.
59. Horowitz A, Reinhardt JP, Kennedy GJ. Major and subthreshold depression among older adults seeking vision rehabilitation services. Am J Geriatr Psychiaty 2005;13:180-7.
60. Shmuely-Dulitzki Y, Rovner BW, Zisselman P. The impact of depression on functioning in elderly patients with low vision. Am J Geriatr Psychiatry 1995;3:325-9.
61. Dong LM. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST Report No. 4. Am J Ophthalmol 2004;138:91-108.
62. Shah VA, Gupta SK, Shah KV, Vinjamaram S, Chalam KV. TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD. Ophthalmic Epidemiol 2004; 11:43-51.
63. Cahill MT, Banks AD, Stinnett SS, Toth CA. Vision-related quality of life in patients with bilateral severe age-related macular degeneration. Ophthalmology 2005;112:152-8.
64. Chia EM, Wang JJ, Rochtchina E, Smith W, Cumming RR, Mitchell P. Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004; 45:71-6.
65. Hassell JB, Lamoureux EL, Keeffe JE. Impact of age related macular degeneration on quality of life. Br J Ophthalmol 2006; 90:593-6.
66. Slakter JS, Stur M. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv Ophthalmol 2005;50:263-73.
67. Moore LW, Constantino RE, Allen M. Severe visual impairment in older women. West J Nars Res 2000; 22:571-95.
68. Fletcher DC, Schuchard RA. Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity. Optom Vis Sci 2006; 83:178-89.
69. Thompson D. VA testing in optometric practice. Part 1: the Snellen chart. Optometry Today/Optics Today 2005;55-7. http://www.optometry.co.uk
70. Thompson D. VA testing in optometric practice. Part 2: Newer chart designs. Optometry Today/Optics Today 2005;22-4. http://www.optometry.co.uk
71. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-90.
72. Encyclopedia - contrast sensitivity. URL: http://www.visionrx.com/ library/enc/enc_contrast.asp. Accessed 14 August 2006.
73. Perimetry. URL: http://en.wikipedia.org/wiki/Perimetry. Accessed 16 August 2006.
74. Department of Health. Certificate of Vision Impairment: explanatory notes for consultant ophthalmologists and hospital eye clinic staff. August 2005. URL: http://www.dh.gov.uk/assetRoot/04/11/86/66/04118066.pdf
75. Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2006;28:36-44.
76. American Academy of Ophthalmology. Age-related macular degeneration. Preferred practice pattern. National Guidelines Clearinghouse; 2000. http://www.guidelines.gov
77. National Institute for Clinical Excellence. Guidance on the use of photodynamic therapy for age-related macular degeneration. Technology Appraisal Guidance. London: NICE; 2003. p. 68.
78. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293:1509-13.
79. Wong D. Avastin is coming? URL: http://www.rcophth.ac.uk/ scientific/scientificnews. Accessed 10 May 2006.
80. Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol 2006; 142:141-3.
81. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355:1409-12.
82. Joint Formulary Committee. British National Formulary. No. 52. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2006.
83. The Royal College of Ophthalmologists. The use of bevacizumab (avastin). URL: http://www.rcophth.ac.uk/scientific/avastin. Accessed 19 September 2006.
84. Department of Health (UK). NHS Reference Costs. 2005. URL: http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/ FinanceAndPlanning/NHSReferenceCosts/fs/en. Accessed 14 September 2006.
85. Bonastre J, Le Pen C, Anderson P, Ganz A, Berto P, Berdeaux G. The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ 2002; 3:94-102.
86. Meads C, Moore D. The clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration. Report No. 24. Birmingham: West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, University of Birmingham; 2001.
87. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004;881107-12.
88. Arnold J, Barbazetto I, Birngruber R, Blumenkranz MS, Bressler SB, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198-207.
89. Genentech. Preliminary Phase III data from head-to-head study of Lucentis shows Lucentis improved vision compared to Visudyne in patients with wet age-related macular degeneration. Press release, 14 January 2006. URL: http://www.gene.com/gene/news/press-releases/ display.do?method=detail&id=9307. Accessed 9 May 2006.
90. Genentech. Fall prescribing information. Lucentis™ (ranibizumab injection). URL: http://www.gene.com/gene/products/information/pdf/ lucentis-prescribing.pdf. Accessed 3 July 2006.
91. Novartis Pharmaceuticals UK. Lucentis (ranibizumab) therapy for the treatment of wet age-related macular degeneration. Evidence submitted to the National Institute for Health and Clinical Excellence, August 2006.
92. Pfizer: Summary of product characteristics. Macugen 0.3 mg solution for injection. URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/ macugen/H-620-PI-en.pdf. Accessed 5 July 2006.
93. Hawkes N. Thousands denied eye drug over NHS costs. URL: http://www.timesonline.co.uk/article/0,,81222185672_2,00.html. Accessed 18 May 2006.
94. Macugen to launch to NICE controversy. URL: http://pharmatimes.com. June 2006.
95. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
96. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2000;355:1432-44.
97. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
98. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration tor photodynamic therapy eligibility (FLAP-study). Ophthalmology 2003;110:400-5.
99. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD Report 4. 2nd ed. York: University of York; 2001.
100. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Year two efficacy results of 2 randomized controlled trials of pegaptanib for neovascular age-related degeneration. Ophthalmology 2006; 113:1508-21.
101. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration. Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113:992-1001.
102. Heier J, Boyer J, Ciulla D, Ferrone T, Jumper P, Gentile J, et al. Ranibizumab combined with verteportin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006; 124:1532-42.
103. Spaide R. New treatments for AMD. Ophthalmology 2006; 113:160-1.
104. FDA Center for Drug Evaluation and Research. Medical Officer's review of NDA 21-756 - Macugen final label. December 2004. URL: http://www.fda.gov/cder/foi/nda/2004/21756_macugen_medr.pdf
105. Pfizer. Macugen (pegaptanib sodium). Submission to the National Institute for Health and Clinical Excellence, 31 July 2006.
106. Zlateva G, Patel M, Shah G, VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Quality of life in patients with age-related macular degeneration: results from the VISION study. Invest Ophthalmol Vis Sci 2006;47:E-Abstract 2152.
107. EyeTech Pharmaceuticals. Dermatologic and Ophthalmic Drugs Advisory Committee meeting. Pegaptanib sodium injection (Macugen). PowerPoint presentation, 2004. URL: http://www.fda.gov/ohrms/dockets/ac/04/slides/ 2004-4053S1_01_EyeTech-Main.ppt. Accessed 23 October 2006.
108. Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, et al. Cost-effectiveness model for age-related macular degeneration: Comparing Macugen to Visudyne. Value Health 2005; 8:A176-7.
109. Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, et al. Cost-effectiveness model for age-related macular degeneration: comparing early and late macugen treatment. Value Health 2005;8:A177.
110. Earnshaw SR, Javitt JC, Graham CN, Brogan AJ, Zlateva GP, Pleil AM, et al. Modeling treatments for subfoveal choroidal neovascularization secondary to age related macular degeneration: cost-effectiveness methods. Value Health 2005; 8:A179.
111. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report no. 3. Arch Ophthalmol 2002; 120:1443-54.
112. Arnold J, Barbezetto I, Birngruber R, Bressler NM, Bressler SB, Donati G, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
113. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
114. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - a value-based reappraisal with 5-year data. Am J Ophthalmol 2005; 140:679-87.
115. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004;88:982-7.
116. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108:2051-9.
117. Sharma S, Bakal J, Sharma SM, Covert D, Shah GK. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005;40:369-77.
118. Greiner R-A. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 2001;16:218-22.
119. Barry SJ, Douglas PR, Becker DL, Hughes MS, Weinstein MC. Economic evaluation of photodynamic therapy (Visudyne®) compared to usual care in the treatment of age related macular degeneration (ARMD) in USA. Value Health 2006; 9:A141-2.
120. Sharma S, Oliver-Fernandez A, Bakal P, Brown GC, Brown MM. Cost-utility of vitamins for the treatment of macular degeneration. Value Health 2002;5:553-4.
121. Scilley K, DeCarlo DK, Wells J, Owsley C. Vision-specific health-related quality of life in age-related maculopathy patients presenting for low vision services. Ophthalmic Epidemiol 2004;11:131-46.
122. Miskala PH, Hawkins BS, Mangione CM, Bass EB, Bressler NM, Dong LM, et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization - SST Report No. 1 [published erratum appears in Arch Ophthalmol. 2003; 121:1513]. Arch Ophthalmol 2003;121:531-9.
123. DeCarlo DK, Scilley K, Wells J, Owsley C. Driving habits and health-related quality of life in patients with age-related maculopathy. Optometry Vis Sci 2003;80:207-13.
124. Hawkins BS. Health- and vision-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at enrollment in a randomized trial of submacular surgery: Submacular Surgery Trials Report No. 5. Arch Ophthalmol 2005; 123:78-88.
125. Berdeaux GH, Nordmann JP, Colin E, Arnould B. Vision-related quality of life in patients suffering from age-related macular degeneration. Am J Ophthalmol 2005;139:271-9.
126. Mitchell J, Wolffsohn JS, Woodcock A, Anderson SJ, McMillan CV, Ffytche T, et al. Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health Qual Life Outcomes 2005;3:25-39.
127. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol 1999;128:45-53.
128. Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol 2004; 88:1270-3.
129. Brown GC, Brown MM, Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 2000;35:127-33.
130. Wakker P, Stiggelbout A. Explaining distortions in utility elicitation through the rank-dependent model for risky choices. Med Decis Making 1995; 15:180-6.
131. Stein JD, Brown MM, Brown GC, Hollands H, Sharma S. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol 2003; 87:8-12.
132. Drummond MF, O'Brien BJ, Torrance GW, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1997.
133. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE; 2004.
134. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36).
135. Curtis L, Netten A. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2005.
136. Zhou SWD. The economic burden of progression in vision loss in Medicare beneficiaries, 1999 to 2003. Data on file. Surrey, UK: Pfizer; 2004.
137. Office for National Statistics. Key health statistics from general practice 1998. Analyses of morbidity and treatment data, including time trends, England and Wales. Series MB6 No. 2, 2000. URL: http://www.statistics.gov.uk/downloads/theme_health/ Key_Health_Stats_1998.pdf
138. Brennan J, Johansen A, Butler J, Stone M, Richmond P, Jones S, et al. Place of residence and risk of fracture in older people: a population-based study of over 65-year-olds in Cardiff. Osteoporos Int 2003;14:515-19.
139. Monthly index of medical specialties. London: Haymarket Medical Publications; 2006.
140. Brazier JE, Kang K, Carlton J, Czoski-Murray CJ. General population survey to obtain values for AMD visual impairment states using lenses - preliminary report. 2006. Appendix 1. Lucentis (ranibizumab) therapy for the treatment of wet age-related macular degeneration. Evidence submitted to the National Institute for Clinical Excellence. Novartis Pharmaceuticals; August 2006.
141. Miller DK, Homan SM. Determining transition-probabilities - confusion and suggestions. Med Decis Making 1994;14:52-8.
142. Mills E, Heels-Ansdell D, Kelly S, Guyatt G. A randomized trial of pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects. J Clin Epidemiol 2007;60:456-60.
143. Sharma S, Brown GC, Brown MM, Shah GK, Snow K, Brown H, et al. Converting visual acuity to utilities. Can J Ophthalmol 2000; 35:267-72.
144. Knapp M, Beecham J, Fenyo A, Hallam A. Community mental health care for former hospital in-patients. Predicting costs from needs and diagnoses. Br J Psychiaty 1995;166 (Suppl 27): 10-18.
145. Scottish Medicines Consortium. Pegoptanib 0.3 mg, solution for intravitreal injection (Macugen). No. 290/06. Accessed 6 November 2006. http://www.scottishmedicines.co.uk
146. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201-4.
147. McLaughlan B, Winyard S. Left to pay for their own. How people facing sight loss from wet age-related macular degeneration are let down by the NHS. Report on the availability of anti-VEGF treatments for wet age-related macular degeneration. Accessed 27 October 2006. http://www.rnib.org.uk/xpedio/groups/public/documents/publicwebsite/ public_macugenreport.doc
148. Evers S, Goossens M, de Ver H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care 2005;21:240-5.
149. Brody BL, Roch-Levecq AC, Gamst AC, Maclean K, Kaplan RM, Brown SI. Self-management of age-related macular degeneration and quality of life: a randomized controlled trial. Arch Ophthalmol 2002; 120:1477-83.
150. Chakravarthy U, Stevenson M. Self-reported visual functioning and quality of life in age-related macular degeneration. Curr Opin Ophthalmol 2005;16:179-83.
151. Stevenson MR, Hart PM, Chakravarthy U, Mackenzie G, Bird AC, Owens SL, et al. Visual functioning and quality of life in the SubFoveal Radiotherapy Study (SFRADS): SFRADS Report 2. Br J Ophthalmol 2005;89:1045-51.
152. Lindblad AS, Clemons TE. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report No. 14. Arch Ophthalmol 2005;123:1207-14.
153. Clemons TE, Chew EY, Bressler SB, McBee W, Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol 2003;121:211-17.